Clinical Study

Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T Cells In Situ and Lymph Node Metastasis

Figure 1

IDO expression in PTs and TDLNs was higher than that in benign diseases at both mRNA and protein levels. The expression of IDO in 26 cases of breast cancer PTs, TDLNs, and normal adjacent tissues and 10 cases of benign breast diseases was detected using qRT-PCR assay and IHC staining method. (a) The IDO mRNA expression in PTs was higher than that in benign diseases but lower than that in TDLNs using the grayscale density ratio of IDO/β-actin (lane 1: IDO in PTs; lane 2: β-actin in PTs; lane 3: IDO in TDLNs; lane 4: β-actin in TDLNs; lane 5: IDO in benign diseases; lane 6: β-actin in benign diseases; lane 7: IDO in normal tissues; lane 8: β-actin in normal tissues; M: DL2000 marker). (b)–(e) The IDO protein was predominantly expressed on cancer cells in breast cancer PTs (b) and in myeloid cell-like karyocytes in TDLNs (c), while less IDO expression was found in mammary ductal cells with hyperplasia in benign diseases (d). No IDO protein expression was detected in normal adjacent tissues (e).
469135.fig.001a
(a)
469135.fig.001b
(b)
469135.fig.001c
(c)
469135.fig.001d
(d)
469135.fig.001e
(e)